Latest Analyst Recommendations for Becton Dickinson

Cornelia Mascio
Aprile 28, 2017

Deutsche Bank maintained Becton Dickinson and Co (NYSE:BDX) rating on Monday, August 10. The firm presently has a $206.00 price target on the medical instruments supplier's stock.

According to Zacks, "Shares of Becton, Dickinson and Company, significantly outperformed the Zacks categorized Medical/Dental-Supplies sub industry year to date". The company is set to report second quarter of fiscal 2017 results on May 4. This represents the Zacks consensus EPS measured at the time of writing. Let's take a look at the latest Wall Street analyst recommendations and target prices for BDX stock over the next year. $5.66M worth of Becton Dickinson and Co (NYSE:BDX) shares were sold by SHERMAN JEFFREY S. $302,694 worth of stock was sold by Gallagher John E on Thursday, December 15.

Becton Dickinson and Co. has 212,825,000 shares in issue which have a share price of 179.07 giving Becton Dickinson and Co. a market capitalisation of 38.11B Dollars. They now have a United States dollars 200 price target on the stock.

Among 12 analysts covering Becton Dickinson (NYSE:BDX), 5 have Buy rating, 1 Sell and 6 Hold. The company had a trading volume of 2,552,552 shares.

On the close of 04/25/2017 Becton, Dickinson and Company (NYSE:BDX) jumped 1.13% to hit $179.07. The firm has a market capitalization of $38.11 billion, a price-to-earnings ratio of 29.81 and a beta of 1.00.

The simple 20 day moving average for Becton, Dickinson and Company is -2.43% and the simple 200-day moving average is at 2.75%. Becton Dickinson and had a net margin of 10.54% and a return on equity of 25.25%. The company earned $2.92 billion during the quarter, compared to analysts' expectations of $2.86 billion. The company's quarterly revenue was down 2.1% on a year-over-year basis.

Analysts await Becton Dickinson and Co (NYSE:BDX) to report earnings on May, 4.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of USA & worldwide copyright legislation. JPMorgan Chase & Co. lowered shares of Becton Dickinson and from an "overweight" rating to a "neutral" rating and dropped their price target for the stock from $190.00 to $175.00 in a research note on Tuesday, January 3rd. The stock was sold at an average price of $180.02, for a total transaction of $5,664,149.28. Following the completion of the transaction, the vice president now directly owns 22,094 shares of the company's stock, valued at approximately $3,977,361.88. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Cribstone Capital Management LLC raised its position in Becton Dickinson and by 320.2% in the first quarter. GWM Advisors LLC now owns 28,213 shares of the medical instruments supplier's stock worth $4,968,000 after buying an additional 4,972 shares during the last quarter. The fund owned 5,759 shares of the medical instruments supplier's stock after selling 380 shares during the period. Trust Co. of Vermont raised its position in Becton Dickinson and by 3.9% in the third quarter. Parkside Financial Bank & Trust now owns 624 shares of the medical instruments supplier's stock worth $113,000 after buying an additional 5 shares in the last quarter. Becton Dickinson and earned a media sentiment score of 0.21 on AlphaOne's scale. Jensen Investment Management Inc owns 2.46 million shares or 5.96% of their USA portfolio. Nelson Van Denburg & Campbell Wealth Management Group LLC bought a new position in Becton Dickinson and during the third quarter valued at $108,000. Cribstone Capital Management LLC now owns 874 shares of the medical instruments supplier's stock worth $161,000 after buying an additional 666 shares in the last quarter.

About BD BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The Company operates through two segments: BD Medical and BD Life Sciences. BD has almost 50,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE